Loading
A Seattle trial of melanoma-targeting T cells treated in the laboratory with the immune signal IL-21 before infusion. The registry lists it as terminated in 2011 and gives no reason.
The registry describes a phase I study of autologous interleukin-21-modulated CD8+ antigen-specific T cells, with cyclophosphamide and aldesleukin, in metastatic melanoma, started in April 2010, with an estimated enrolment of 12 (ClinicalTrials.gov NCT01106235). Its overall status is terminated, with primary completion in November 2011 and no reason for stopping recorded; Cassian Yee is listed as principal investigator (ClinicalTrials.gov NCT01106235). No results are posted.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/